Clinical Trial Update: A Pilot Feasibility Study of Oral 5-Fluorocytosine and Genetically-Modified Neural Stem Cells Expressing E.Coli Cytosine Deaminase for Treatment of Recurrent High Grade Gliomas [Phase 1]

View source ↗

Summary

Phase 1 feasibility trial evaluating oral 5-fluorocytosine in combination with genetically modified neural stem cells expressing E. coli cytosine deaminase for …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Astrocytoma
• Anaplastic Oligoastrocytoma
• Anaplastic Oligodendroglioma
• Glioblastoma
• Gliosarcoma
• High-grade Glioma

Drugs mentioned

• 5-fluorocytosine (5-fluorocytosine)
• neural stem cells expressing E. coli cytosine deaminase (neural stem cells expressing E. coli cytosine deaminase)

Snippet

Sponsor: City of Hope Medical Center | Conditions: Adult Anaplastic Astrocytoma, Recurrent Grade III Glioma | Phase 1 | Status: COMPLETED